Cancer patients are at particular risk for COVID-19 infection and adverse outcomes associated with the disease. A nationwide cohort study of over 1000 cancer patients diagnosed with COVID-19 reported a 13% mortality rate due to complications, dramatically higher than that seen in subjects without cancer. In addition to the direct impact of COVID-19 infection in cancer patients, the COVID-19 pandemic has resulted in a reallocation of hospital and medical resources to the care of patients with COVID-19. This resource strain has resulted in delays and discontinuation of treatments for chronic diseases such as cancer. Delays and interruptions in chemotherapy, radiotherapy and surgery are common among cancer patients. Our preliminary data strongly suggests that minority and socioeconomically disadvantaged cancer patients are at particular risk for interruptions in their cancer care. The overarching goal of this proposal is to determine the interplay of race and neighborhood socioeconomic factors on cancer care delivery for oncology patients during a period of wide community spread of COVID-19. We will utilize large scale datasets to analyze factors associated with COVID- 19 infection among a racial and socioeconomically diverse group of cancer patients and perform quantitative surveys in this population to determine how COVID-19 has impacted receipt of cancer care and enrollment onto clinical trials. Specifically, we will link data from 2,000 patients with cancer diagnosed between December 3, 2019 and August 1, 2020 and receiving cancer treatment at Columbia University Irving Medical Center in New York City to census and real estate tax assessment data to determine the association between race and neighborhood socioeconomic status and COVID-19 infection rates. We will then survey a diverse subset of these cancer patients (n = 150, 75 non-Hispanic whites and 75 Hispanic and black) to quantitatively assess knowledge of, attitudes toward, and behaviors related to SARS-CoV-2 and determine how community social and economic indicators, stress, coping style and social support have influenced cancer treatment delays and clinical trial participation during the COVID-19 pandemic. We hypothesize that minority cancer patients and those residing in neighborhoods with low socioeconomic status are increased risk for COVID-19 infection and are more likely to experience treatment delays and disruptions of their cancer care and clinical trial participation. The proposed work will comprehensively determine how racial and socioeconomic factors influence COVID-19 infection and care delivery among cancer patients. We will leverage our unique population of racial and socioeconomically diverse patients from a cancer center at the epicenter of COVID-19 infection in New York City. We anticipate that data from these studies will identify demographic factors associated with a particularly high risk for COVID- 19 infection and cancer treatment alterations that may impact survival. Ultimately, these data will be utilized to develop pragmatic interventions to help reduce the burden of COVID-19 on cancer care in vulnerable and minority populations.

Public Health Relevance

The overarching goal of this proposal is to determine the interplay of race and neighborhood socioeconomic factors on cancer care delivery for oncology patients during a period of wide community spread of COVID-19. We will utilize large scale datasets to analyze factors associated with COVID-19 infection among a racial and socioeconomically diverse group of cancer patients and perform quantitative surveys in this population to determine how COVID-19 has impacted receipt of cancer care and clinical trial participation. We anticipate that data from this study will identify factors associated with a particularly high risk for COVID-19 infection and cancer treatment alterations that may impact survival that will be utilized to develop pragmatic interventions to help reduce the burden of COVID-19 on cancer care in vulnerable and minority populations with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
3UG1CA189960-07S1
Application #
10202811
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
St Germain, Diane
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hillyer, Grace Clarke; MacLean, Sarah A; Beauchemin, Melissa et al. (2018) YouTube Videos as a Source of Information About Clinical Trials: Observational Study. JMIR Cancer 4:e10060
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Dickson, M A; Mahoney, M R; Tap, W D et al. (2016) Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol 27:1855-60
Lassman, Andrew B; Cloughesy, Timothy F (2016) Biomarkers in NOA-04: another piece to the puzzle. Neuro Oncol 18:1467-1469
Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31
Schaff, Lauren R; Lassman, Andrew B (2015) Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas? Semin Radiat Oncol 25:203-9
Iwamoto, Fabio M; Lassman, Andrew B (2015) Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro Oncol 17:174-6